Opinion|Videos|February 21, 2025
Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL
Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting emerging data that may refine their use in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), particularly in optimizing treatment duration and sequencing to improve patient outcomes.
Advertisement
Episodes in this series
- Were there any particularly exciting updates or data presented at ASH 2024 that could influence how BTK inhibitors are used in clinical practice for CLL and MCL?
Advertisement
Related to this article
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Sacral neuromodulation is still considered the gold standard for refractory overactive bladder, with tibial nerve stimulation a less invasive option.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
The Omaha-based practice will hand its inbound faxes and document management to artificial intelligence (AI) agents, with outside records retrieval to follow.
Advertisement
Advertisement
Trending on AJMC
1
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
2
CMS Moves TIC Reporting to Quarterly, Sets Drug File Timeline
3
5 Things to Know if Retatrutide Is Classified as a Biologic
4
Will Cancer Care Come Home by 2030? PCOC Panelists Differ on Strategy
5